Computer Software Assurance Begins With the Intended Use

Lukas
By

A risk-based assurance plan needs a clear understanding of what the software does and what could go wrong. That reasoning should guide the evidence selected for the relevant use.

Establish the applicable context

Determine what the software does in the process and which functions could affect production or the quality management system. A broad label such as enterprise software does not resolve the question. The relevant assessment concerns the actual use of the function and the consequences of failure.

The guidance should not be presented as a blanket statement that CSV has disappeared or that pharmaceutical validation obligations no longer apply. Organizations operating across several regulated contexts need to distinguish the frameworks relevant to each system and use case.

Choose assurance activities for the risk

A risk-based approach asks what evidence is appropriate to establish confidence in the intended use. Depending on the function and context, assurance activities may involve different forms of testing and supporting information. The rationale should explain why the selected activity addresses the identified concern.

For a hypothetical workflow, a calculation used in a quality decision may deserve focused challenge of inputs, boundaries and outputs. A low-risk administrative feature may justify a different depth of activity. Applying the same script format everywhere can obscure those differences rather than improve assurance.

Preserve the decision and its basis

Record the intended use, risk reasoning, activities performed, issues identified and conclusion. The record should be sufficient to explain what confidence was established and what limitations remain. Reducing unnecessary documentation does not mean removing the information needed to understand a decision.

Validfor’s test management offering describes scripted and unscripted approaches. Its catalogue connects risk and test work, making the platform relevant to proportionate assurance planning. The current FDA CSA guidance should be used within its stated medical-device production and quality-system scope.

A useful assurance plan explains why the chosen activities address the relevant risk. The quality of that reasoning matters more than the volume of completed paperwork.

In recent years, validation processes across the pharmaceutical industry have been undergoing a major transformation. Workflows that were traditionally managed through paper documentation, spreadsheets and manual review cycles are increasingly moving toward digital validation platforms. As a result, life sciences organizations often evaluate solutions such as Kneat, Validfor, ValGenesis, MasterControl and Veeva when modernizing validation lifecycle management and compliance documentation.

Share This Article